Solid Biosciences nabs $50 mln Series C
Cambridge, Massachusetts-based Solid Biosciences, which is focused on treating Duchenne muscular dystrophy, has secured $50 million in Series C financing. RA Capital Management and Bain Capital Life Sciences led the round with participation from other investors that included RTW Investments, Foresite Capital, Cormorant Asset Management LLC, Perceptive Advisors and Janus Capital Management.
30 March 2017•1 min read
